Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections

Revista Espanola de Quimioterapia

Volumn 22, Issue 2, 2009, Pages 57-61

  Granizo, J J ^a   Aguilar, L ^b   Gimenez, M J ^b   Coronel, P ^c   Gimeno, M ^c   Prieto, J ^b  

^a Quirón University Hospital Pozuelo de Alarcon   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c Scientific Consultants   (Spain)

Author keywords

Adverse events; Cefditoren; Clinical trials; Respiratory tract infections; Safety

Indexed keywords

CEFDITOREN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PENICILLIN DERIVATIVE;

ABDOMINAL PAIN; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DRUG SAFETY; DYSPEPSIA; HUMAN; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SINUSITIS; TONSILLITIS; TREATMENT OUTCOME; VAGINITIS; CHEMICALLY INDUCED DISORDER; COMMUNICABLE DISEASE; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL DISEASE; MALE; META ANALYSIS; PHASE 3 CLINICAL TRIAL; STATISTICS; SUPERINFECTION;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS, PHASE III AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; PENICILLINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS; SUPERINFECTION; VAGINITIS;

EID: 70349573325     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Llor C. Consideraciones a la hora de la prescripción antibiótica en atención primaria. Med Clin Monogr (Barc) 2004;5:52-77.
2. Mogyoros M. Challenges of managed care organisations in treating respiratory tract infections in an age of antibiotic resistance. Am J Man Care 2001;7(Suppl. 6):163-169 (Pubitemid 32590861)
3. Armstrong GL, Pinner RW. Outpatient visits for infectious diseases in the United States, 1980 through 1996. Arch Intern Med 1999;159:2531-2536
4. Linder JA, Stafford RS. Antibiotic treatment of adults with sore throat by community primary care physicians: a national survey, 1989-1999. JAMA 2001;286:1181-1186
5. Gwaltney JM Jr. Acute community-acquired sinusitis. Clin Infect Dis. 1996;23:1209-1223
6. Jiménez-Ruiz CA, Masa F, Miravitlles M, Gabriel R, Viejo JL, Villasante C, et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001;119:1365-1370
7. Ball P, Make B. Acute exacerbations of chronic bronchitis: an international comparison. Chest 1998:113(Suppl. 3):31-40. (Pubitemid 28145416)
8. Gump DW, Phillips CA, Forsyth BR, McIntosh K, Lamborn KR, Stouch WH. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976;113:465-474
9. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754
10. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-1433
11. Zalacain R, Torres A, Celis R, Blanquer J, Aspa J, Esteban L, et al. Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur Respir J 2003;21:294-302.
12. Agencia española de medicamentos y productos sanitarios https://sinaem4.agemed.es/consaem/fichasTecnicas.do/metodo=detalleForm.
13. US Food and Drug Administration www.fda.gov.
14. Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the perpathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Clin Ther 2006;28:2061-2069
15. Granizo JJ, Giménez M, Barberàn J, Coronel P, Gimeno M, Aguilar L. Efficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trials. Rev Esp Quimioterap 2008;21:14-21. (Pubitemid 351897525)
16. Rouveix B. Antibiotic safety Assessment. Int J Antimicrob Agents 2003;21:215-221
17. Huovinen P, Cars O. Control of antimicrobial resistance : time for action. The essentials of control are already well known. BMJ 1998;317:613-614
18. th Ed. 2008.
19. Siquier B, Sánchez-Alvarez J, García-Mendez E, Sabriá M, Santos J, Pallarés R, et al. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2006;57:536-545
20. Garau J, Twynholm M, Garcia-Mendez E, Siquier B, Rivero A; 557 Clinical Study Group. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J Antimicrob Chemother. 2003;52:826-836
21. MacDonald TM, Beardon PH, McGilchrist MM, Duncan ID, McKendrick AD, McDevitt DG. The risks of symptomatic vaginal candidiasis after oral antibiotic therapy. Q J Med. 1993;86:419-424
22. Wilton L, Kollarova M, Heeley E, Shakir S. Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England. Drug Saf 2003;26:589-597 (Pubitemid 36724098)
23. B phenotype of macrolide resistance in Spain, 1999 to 2005. Antimicrob Agents Chemother 2007;51:1228-1233
24. García-Cobos S, Campos J, Lazaro E, Román F, Cercenado E, Garcia-Rey C, et al. Ampicillin-resistant non-β-lactamase producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime. Antimicrob Agents Chemother 2007;51:2564-2573
25. García-de-Lomas J, Lerma M, Cebrián L, Juan- Bañón JL, Coronel P, Giménez MJ, et al. Influence of Haemophilus influenzae beta-lactamase production and/or ftsl gene mutations on in vitro activity of and susceptibility rates to aminopenicillins and second and third-generation cephalosporins. Int J Antimicrob Agents 2007;30:190-192
26. Soriano F, Granizo JJ, Fenoll A, Gracia M, Fernández-Roblas R, Esteban J, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance program. J Chemother 2003;15:107-112
27. Soriano F, Granizo JJ, Fernández-Roblas R, Esteban J, Gadea I, Gracia M, et al. Antimicrobial susceptibilities of Streptococcus pyogenes isolated from adult patients with respiratory tract and skin and soft tissue infections in four southern European countries. J Chemother 2003;15:293-295